Hana Pharm Co., Ltd.

A293480

KR7293480000

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
12,950 ^KRW	-0.38%		-0.46%	-7.17%

2023	Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore	MT
2023	Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore	MT

Hana Pharm Co., Ltd authorizes a Buyback Plan.

July 26, 2019

The Board of Directors of Hana Pharm Co., Ltd has authorized a buyback plan on July 26, 2019.

Latest news about Hana Pharm Co., Ltd.

Singapore Shares Return to Green; Hyphens Pharma Rises 5% on Deal to Develop Sedation Drug in Singapore	18/23/18	MT
Hyphens Pharma to Develop, Commercialize Hana Pharm's Sedation Drug in Singapore	18/23/18	MT
Hyphens Pharma Pte. Ltd. Signs an Exclusive Sub-License and Supply Agreement with Hana Pharm Co., Ltd. to Develop and Commercialise Byfavo® 20mg in Singapore	17/23/17	CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine	12/22/12	MT
Hana Pharm Receives Market Approval for Byfavo (Remimazolam) in Procedural Sedation in South Korea	31/21/31	CI
Hana Pharm Informs PAION AG About the Launch of Byfavo™ (Remimazolam) for the Use in General Anesthesia in South Korea	07/21/07	CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 19, 2019, has expired.	18/20/18	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	05/20/05	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	05/20/05	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on August 6, 2019.	05/20/05	CI
Hana Pharm Co., Ltd's Equity Buyback announced on August 6, 2019, has expired with 87,239 shares, representing 0.54% for KRW 1,997.13 million.	05/20/05	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 9, 2019.	08/20/08	CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 9, 2019, has expired.	08/20/08	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on July 26, 2019.	30/19/30	CI
Hana Pharm Co., Ltd's Equity Buyback announced on July 26, 2019, has expired with 84,312 shares, representing 0.53% for KRW 1,997.08 million.	30/19/30	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 1,000 million worth of its shares.	19/19/19	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	19/19/19	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	06/19/06	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	06/19/06	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	26/19/26	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	26/19/26	CI
Hana Pharm Co., Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.	09/19/09	CI
Hana Pharm Co., Ltd authorizes a Buyback Plan.	09/19/09	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.	20/19/20	CI
Tranche Update on Hana Pharm Co., Ltd's Equity Buyback Plan announced on December 21, 2018.	20/19/20	CI

HANA PHARM CO., LTD is a Korea-based company mainly engaged in the manufacturing and distribution of specialty pharmaceuticals. The companyâs main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The Company also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
HANA PHARM CO., LTD.	-7.17%	169M
MERCK KGAA	+17.45%	79.28B
KYOWA KIRIN CO. LTD.	+7.97%	8.74B
SK BIOPHARMACEUTICALS CO., LTD.	-16.33%	4.84B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.22%	4.74B
YUHAN CORPORATION	+2.18%	3.87B
INDIVIOR PLC	+21.18%	2.46B
BETTA PHARMACEUTICALS CO., LTD.	-26.79%	2.18B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+15.12%	2.09B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-36.56%	1.98B

Specialty & Advanced Pharmaceuticals

Hana Pharm Co., Ltd.

Equities

A293480

KR7293480000

Pharmaceuticals

Hana Pharm Co., Ltd authorizes a Buyback Plan.

Latest news about Hana Pharm Co., Ltd.

Chart Hana Pharm Co., Ltd.

Company Profile

Sector Specialty & Advanced Pharmaceuticals